Haemostasis action of VELSEAL-T in a haemophilia A patient with external bleeding

Open access

Abstract

VELSEAL-Tis an innovative haemostatic medical device for the control of bleeding. Incorporating a clotting agent (thrombin) and anti-fibrinolytic agent (tranexamic acid), it enables rapid coagulation when blood flows into the dressing, leading to sealing and stabilisation of wound surfaces. A 36-year-old known to have mild haemophilia A presented with profuse bleeding from the forehead after injury following a fall on concrete surface. He attended hospital after 18 hours of injury as bleeding continued as soon as pressure was released from the injury site. A VELSEAL-T patch was applied to the injury site with the patient’s full consent. The bleeding stopped after 60 seconds, but the patient was instructed to hold the patch in place for a further 60 seconds. After two minutes of tight pressure application, there was no more oozing of blood from the injury site. This case shows that VELSEAL-T can be used as an aid in stopping external bleeding in haemophilia patients. Further trials should be undertaken to evaluate the safety and efficacy of this product.

References

  • 1. Skinner MW. WFH: closing the global gap - achieving optimal care. Haemophilia 2012; 18 (Suppl 4): 1-12.

  • 2. Lee CA. Historical introduction. In: Lee CA, Berntorp E, Hoot K, eds.Textbook of Hemophilia, 2nd ed. West Sussex: Wiley- Blackwell, 2010: 1-6.

  • 3. van den Berg HM, Fischer K. Phenotypic - genotypic relationship. In: Lee CA, Berntorp E, Hoots K, eds. Textbook of Hemophilia, 2nd ed. West Sussex: Wiley-Blackwell, 2010: 33-7.

  • 4. Mannucci PM, Tuddenham EG. The hemophilias- from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.

  • 5. Rodeghiero F, Castaman G. von Willebrand disease: epidemiology. In: Lee CA, Berntorp E, Hoots K, eds. Textbook of Hemophilia, 2nd ed. West Sussex: Wiley-Blackwell, 2010: 286-93.

  • 6. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 569-76.

  • 7. Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitors development in Chinese patients with haemofilia A. Haemophilia 2010; 16(4): 632-9.

  • 8. Bitchell TC. Distúrbioshereditários da coagulação. In: Lee GR, Bitchell TC, Foerster J, et al. Wintrobe Hematologia Clinica, vol II, 9th ed. São Paulo: Editora Manole, 1998: 1562-616.

  • 9. da Silva PH, Hashimoto Y. Coagulação:Visão Laboratorial da Hemostasia Primária e Secundária. Rio de Janeiro: Livraria e Editora Revinter, 2006.

  • 10. Giannelli F, Choo KH, Rees DJG, et al. Gene deletions in patients with haemophilia B and antifactor IX antibodies. Nature 1983; 303: 181-2.

  • 11. World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2011. Montréal: WFH; 2013. Available from: http://www1.wfh.org/publications/files/pdf-1488.pdf, accessed 13 November 2017.

  • 12. Kar A, Phadnis S, Dharmarajan S, Nakade J.Epidemiology & social costs of haemophilia in India. Indian J Med Res2014; 140: 19-31.

  • 13. Dutta A, Dutta TS, Kar S, et al. Study on clinical presentation of factor deficient patients presenting to a tertiary care centre of North East India. Journal of Medical Science and Clinical Research 2016; 4(7),doi:10.18535/jmscr/v4i7.57.

  • 14. Dutta A, Dutta TS, Dey P. Clinical profile of haemophilia patients of upper Assam- a hospital-based study. J Evolution Med Dent Sci 2017;6(37):2990-3, doi: 10.14260/ Jemds/2017/645.

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 13 13 13
PDF Downloads 2 2 2